Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T18:52:06.067Z.
Calculation as of: 2026-10-06T18:52:06.067Z.
Quote observation: 2026-10-06T18:48:26.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0dc40ddd6b0c815ea8fb06d6c0f10798674f4babd9a38c246e46e89e51900236
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$49.44M
EV/EBIT Ratio
N/A
TTM Avg
36.45x
3Y Avg
39.02x
5Y Avg
39.02x
Market Cap
$49.47M
EV/EBIT Ratio
N/A
TTM Avg
398.45x
3Y Avg
398.45x
5Y Avg
398.45x
Market Cap
$49.55M
EV/EBIT Ratio
N/A
TTM Avg
11.96x
3Y Avg
9.90x
5Y Avg
11.19x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lite Strategy, Inc. (LITS) | $47.81M | N/A | N/A | N/A | N/A |
| Instil Bio, Inc. (TIL)vs › | $46.73M | N/A | N/A | N/A | N/A |
| Celularity Inc. (CELU)vs › | $46.31M | N/A | N/A | N/A | N/A |
| TELA Bio, Inc. (TELA)vs › | $49.21M | N/A | N/A | N/A | N/A |
| Apollomics, Inc. (APLM)vs › | $48.82M | N/A | N/A | N/A | N/A |
| Microbot Medical Inc. (MBOT)vs › | $49.44M | N/A | 36.45x | 39.02x | 39.02x |
| Precision Optics Corporation, Inc. (POCI)vs › | $49.47M | N/A | 398.45x | 398.45x | 398.45x |
| Sensus Healthcare, Inc. (SRTS)vs › | $49.55M | N/A | 11.96x | 9.90x | 11.19x |
| INmune Bio, Inc. (INMB)vs › | $49.18M | N/A | N/A | N/A | N/A |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $49.94M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
